MyFinsight
Home
Blog
About
Contact
Proceeds from the
issuance of common stock
$17,214K
Proceeds from issuance of
common stock under...
$354K
Proceeds from exercise of
stock options
$1K
Net cash, cash
equivalents, and restricted...
$16,897K
Canceled cashflow
$672K
Net increase
(decrease) in cash, cash...
$6,585K
Canceled cashflow
$10,312K
Equity financing costs
$481K
Other
-$158K
Payment of debt issuance
costs
$28K
Repayment of term loan and
notes payable
$5K
Depreciation and
amortization
$1,396K
Share-based compensation
expense
$1,115K
Accrued interest,
amortization of debt issuance...
$332K
Provision for credit
losses
$24K
Inventory excess and
obsolescence
$20K
Other long-term
assets
-$19K
Reduction (accretion) of
lease right-of-use...
$19K
Impairment loss on
intangible assets
$5K
Net cash, cash
equivalents, and restricted...
-$10,168K
Net cash, cash
equivalents, and restricted...
-$144K
Canceled cashflow
$2,930K
Revenues
$25,555K
Net loss
-$7,793K
Accounts payable and
other accrued...
-$2,344K
Other current assets
$1,366K
Purchase of property and
equipment
$81K
Patent costs and
intangible asset...
$63K
Canceled cashflow
$25,555K
Deferred revenue
-$766K
Accounts receivable
$488K
Current and long-term
operating lease...
-$341K
Employee related
expenses (less...
$19,209K
Direct costs and
expenses (less employee...
$2,712K
Sales and marketing
education and event...
$2,211K
Interest expense
$1,977K
Contracted services
expenses
$1,689K
Other segment items
$1,405K
Depreciation and
amortization expense
$1,396K
Share-based compensation
expenses
$1,115K
Occupancy and equipment
service expenses
$996K
Clinical trials and
associated costs
$638K
Back
Back
Cash Flow
BIODESIX INC (BDSX)
BIODESIX INC (BDSX)
source: myfinsight.com